PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Study type: Observational

Funder types: Industry

Identifiers

NCT00936208

502.584

Details and patient eligibility

About

PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular events. The study aims to evaluate the safety, efficacy and protection of Micardis 80mg/Micardis plus 80/12.5mg from cardiovascular risks in patients with essential hypertension

Enrollment: 3,184 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female
• Aged 20 to 80 years old.
• adult with essential hypertension - either newly diagnosed and untreated, or previously treated and uncontrolled
• Sitting blood pressure: systolic BP > 140 mmHg but < 180 mmHg, and/or diastolic BP > 90 mmHg but < 110 mmHg)
• At least one cardiovascular known risk factor other than hypertension: diabetes/hyperglycaemia, cholesterol /dyslipidemia, a previous cardiovascular event, target organ damage, family history of hypertension or cardiovascular diseases, old age defined as > 55 years (Males), > 65 years (Females), smoking, overweight or obese patients or a combination of above risk factors
• Patients who are assessed to benefit from the intake of angiotensin II receptor blocker (ARB) monotherapy or as add-on medication

Exclusion criteria

• Patients with contraindications to Telmisartan use (as per the Micardis® Tablets package insert).
• Known hypersensitivity to the active ingredient or to any of the excipients of Micardis® .
• Any other clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications.
• Patients participating in any other clinical trial.
• Patients already on Micardis® alone or combination
• Pregnant females, or females breast feeding.

Trial design

3,184 participants in 1 patient group

Essential hypertensive men and women